Alkeus Pharma

Alkeus Pharmaceuticals, Inc. is a biopharmaceutical company focused on preserving sight for people affected by degenerative retinal diseases. Now part of Tarsus Pharmaceuticals, Alkeus describes the transition as a new chapter in its effort to advance potential sight-preserving medicines.

Its research centers on preventing the buildup of toxic vitamin A dimers in the retina, which are associated with Stargardt disease and geographic atrophy secondary to age-related macular degeneration. The company’s oral investigational therapy, gildeuretinol, is designed to reduce vitamin A dimerization without modulating the visual cycle; it is not presented as an approved treatment. Alkeus’s clinical program includes studies in Stargardt disease, including NORTHSTAR and TEASE, and the SAGA study in geographic atrophy.

The company highlights Stargardt disease as a rare genetic condition that can cause severe vision loss in children and adults, with no approved treatment identified on its site. Alkeus also shares patient perspectives, clinical-trial information, scientific updates, and career opportunities as it works to address unmet needs in retinal disease